National Cancer Institute - NCI Division of Cancer Treatment and ...

DIVISION OF CANCER TREATMENT AND DIAGNOSIS
The Division of Cancer Treatment and Diagnosis
collaborates with other National Cancer Institute components
as the world‘s largest sponsor of clinical cancer research.
The Division of Cancer Treatment and
Diagnosis (DCTD) collaborates with
other National Cancer Institute (NCI)
components as the world’s largest sponsor
of clinical cancer research.
The multidisciplinary staff members of
DCTD identify the most promising areas
of science and technology for development
of better diagnostic and therapeutic
interventions for patients with cancer. A
roster listing full-time DCTD staff as well
as contractors is appended to this report.
The division takes prospective detection
and treatment leads, facilitates their paths
to clinical application, and expedites the
initial and subsequent large-scale testing
of new agents and interventions in
patients. By determining the highest
priority questions that can be examined
in the laboratory and through clinical
trials, DCTD ensures that appropriate
mechanisms and resources are available
for the development of novel interventions
for the wide range of cancers
affecting children and adults.
Another major objective for the division
is increasing the scientific depth at which
new treatments are being evaluated
while coordinating the administration
and conduct of clinical trials with all
other NCI components involved in the
pursuit of clinical studies.
O V E R V I E W
DCTD scientists support programs to
pursue high-risk research that may yield
great benefits for patients with cancer
but may be too difficult or risky for
industry or academia to undertake. This
includes a particular emphasis on the
development of unique molecular
signatures for cancer and molecular
assays and imaging techniques that will
guide oncologic therapy in the future.
D I V I S I O N O F C A N C E R T R E A T M E N T A N D D I A G N O S I S ■ 1